[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mid and South Essex NHS Foundation Trust\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":120},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,68,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100618852","comprehensive-diagnostic-assessment-of-coronary-endothelial-function-impairment-and-vasospasm-with-continuous-thermodilution-in-patients-with-suspected-coronary-microvascular-and-vasomotor-dysfunction-100618852",false,"NCT07337005","CompREhensive Diagnostic Assessment of Coronary Endothelial Function Impairment and Vasospasm With CoNtinuous ThErmodilution in Patients With Suspected Coronary Microvascular and Vasomotor Dysfunction","REDEFINE-CMD","Inclusion Criteria:\n\n1. Patients with symptoms suggestive of angina.\n2. Evidence of unobstructed coronary arteries on invasive or non-invasive coronary angiography (coronary stenosis \\\u003C50% and \u002For FFR \\>0.80).\n3. Above the age of 18.\n4. The subject has been informed of the nature of the study, agrees to its provisions and has signed written informed consent.\n\nExclusion Criteria:\n\n1. Pregnancy.\n2. Contraindication to angiography and\u002For physiological assessment with adenosine or acetylcholine.\n3. Previous coronary artery bypass graft (CABG).\n4. Moderate to severe valvular heart disease.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this observational study is to learn more about the diagnosis of coronary endothelium function and coronary vasospasm using a dedicated invasive protocol in patients who has angina without obstruction in their main heart arteries. The main question it aims to answer is the feasibility, reproducibility, and safety of this invasive protocol:\n\nDoes this invasive protocol diagnose coronary endothelial dysfunction and vasospasm without issues?\n\nParticipants already having invasive coronary angiogram and physiological studies will undergo additional physiological measurements during the same procedure.\n\nParticipants will enrol in a symptoms and quality of life questionnaire using dedicated questionnaires and a mobile application to assess the burden of their symptoms before and after the invasive procedure and up to 12 months follow up.\n\nA subset of participants will undergo a repeat set of these measurements to assess reproducibility of the invasive protocol.\n\nA subset of the participants will also undergo a cardiac MRI to assess correlation with the invasive protocol measurements.",[26,27],"Coronary Microvascular Dysfunction (CMD)","Vasospasm, Coronary","NOT_YET_RECRUITING","2026-01-07",{"date":31,"type":32},"2026-01-13","ACTUAL",{"date":34,"type":20},"2025-12-15",{"date":36,"type":20},"2027-12",{"name":38,"class":39},"Mid and South Essex NHS Foundation Trust","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100606346","quad-hf---prospective-registry-of-patients-with-incident-heart-failure-and-left-ventricular-ejection-fraction-50-100606346","NCT07174362","QUAD-HF - Prospective Registry of Patients With Incident Heart Failure and Left Ventricular Ejection Fraction \u003C50%","QUAD-HF Registry - A Prospective Registry of Patients With Incident Heart Failure and Left Ventricular Ejection Fraction of \u003C50%","QUAD-HF","Inclusion Criteria:\n\n1. Age \\>18 years\n2. Newly diagnosed Heart Failure with a Left Ventricular Ejection Fraction \\\u003C50% (≤12 Weeks prior to enrolment).\n3. Able and willing to consent.\n\nExclusion Criteria:\n\n1. LVEF 50% or more at time of diagnosis\n2. Palliative care\n3. Unable or unwilling to give consent",{"count":49,"type":20},4000,"60 Months","OBSERVATIONAL","The QUAD-HF registry is an observational study that would enroll patients in the United Kingdom, who have been newly diagnosed with heart failure and a left ventricular ejection fraction \\\u003C50%. We plan to assess clinical outcomes in these patients, such as hospitalization and death, in relation to their diagnosis, implementation of guidelines and type of treatments these patients have received.",[54],"Heart Failure",[56,54,57],"Observational Cohort","Longitudinal","RECRUITING","2025-12-08",{"date":61,"type":32},"2025-12-16",{"date":63,"type":32},"2025-10-06",{"date":65,"type":20},"2031-11",{"name":38,"class":39},2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100606274","bioimpedance-integration-for-optimized-fluid-management-in-decompensated-heart-failure-100606274","NCT07173426","Bioimpedance Integration for Optimized Fluid Management in Decompensated Heart Failure","BIO-HF","Inclusion Criteria:\n\n1. Age \\>18 years\n2. Patients with hospitalised with a decompensated episode of Heart Failure regardless of Ejection Fraction\n3. Able and willing to consent.\n\nExclusion Criteria:\n\n1. Patients on a palliative care pathway and\u002For estimated life expectancy \\\u003C3 months\n2. Patients admitted to ITU\u002F on intensive care support.\n3. Patients currently taking part in any trials investigating new heart failure drug or interventional treatment.\n4. Patients requiring Renal Replacement Therapy.\n5. Patients unable or unwilling to give consent.",{"count":76,"type":20},255,[23],"The goal of this clinical trial is to test whether using Bioimpedance Analysis (BIA) can help manage fluid levels in patients with heart failure who are admitted to the hospital with worsening symptoms. The main questions it aims to answer are:\n\n1\\. Does BIA-guided fluid management reduce the need for extra treatment (in the form of diuretics which helps remove excess fluid from the body) or re-hospitalization for heart failure within 90 days after discharge?\n\nResearchers will compare a group receiving BIA-guided treatment to a standard care group to see if BIA provides better results in managing fluid levels.\n\nParticipants will be randomly assigned to one of two groups:\n\nBIA-Guided Treatment Group: Have BIA measurements done within 24 hours of admission and throughout their hospital stay to guide diuretic treatment.\n\nStandard Care Group: Have BIA measurements taken at admission and discharge, but the results will not be shared with the clinical team, who will manage fluid levels as usual.\n\nAll patients will attend a follow-up visit in 2-4 weeks after discharge where the patient will undergo standard health checks, blood tests, and a questionnaire about how heart failure affects their quality of life.\n\nThe investigators will then compare both groups for the primary outcome measure, which is the rates of rehospitalisation or need for additional decongestive treatment, within 90 days of discharge from hospital.",[54,80],"Decompensated Heart Failure",[82,80,83],"Bioimpedance Analysis","Fluid Assessment","2025-09-12",{"date":86,"type":32},"2025-09-15",{"date":88,"type":32},"2024-12-30",{"date":90,"type":20},"2026-12-01",{"name":38,"class":39},1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100564356","post-market-study-of-cerament-vg-in-pedal-osteomyelitis-100564356","NCT06628115","Post Market Study of Cerament V\u002FG in Pedal Osteomyelitis","Post-market Study of Cerament V\u002FG in Foot Osteomyelitis","Cerament 2","Inclusion Criteria:\n\n* 18 years +\n* Informed consent\n* Operated on for foot sepsis with limb salvage intent.\n* Positive bone biopsy from forefoot or midfoot or positive pus culture from exposed bone\n* Adequate vascularity (1+ palpable pedal pulse, biphasic or triphasic ankle waveforms, or successful revascularisation procedure same admission)\n* Compliant with offloading footwear and diabetic medication\n\nExclusion Criteria:\n\n* Allergy or contraindication to gentamicin\u002Fvancomycin\n* Life expectancy \\&amp \\<1 year\n* Unable to make follow up appointments at study centre.\n* Patients with necrotizing infections\n* Gentamicin or vancomycin resistant organism\n* Untreated peripheral arterial disease in angiosome of wound.\n* Buerger's disease\n* Vasculitides\n* Systemic immunosuppressive therapy\n* Pregnancy\n* Breastfeeding\n* Untreated thyrotoxicosis\n* Mysathenia gravis\n* Calcium metabolism disorder\n* Patients taking metformin with estimated glomerular filtration rate (eGFR) \\> 30ml\u002Fmin\u002F1.72m2",{"count":102,"type":20},25,[23],"The goal of this clinical trial is to look at the outcomes of patients who have had bone infection of their feet treated with a licensed antibiotic paste. The main question it aims to answer is:\n\n• How does the bone infection heal in response to the antibiotic paste?\n\nParticipants will:\n\n* Undergo standard surgery to remove dead bone and drain any pus.\n* Antibiotic paste is injected directly into the middle of the bone at surgery. This is instead of receiving antibiotics directly into their bloodstream for 6 weeks.\n* Recieve one week of tablet antibiotics.\n* Visit clinic 1 month after surgery for a normal clinical appointment. After, a research team member will ask the participant a few questions. The participant will also have a foot x-ray, wound photograph and fill out a short questionnaire.\n* Visit clinic 6 months and 12 months following the surgery. A research team member will ask the participant a few questions. The participant will also have a foot x-ray, wound photograph and fill out a short questionnaire.",[106],"Osteomyelitis - Foot",[108,109,110,111],"osteomyelitis","antimicrobial","bone void filler","cerament","2024-10-03",{"date":114,"type":32},"2024-10-04",{"date":116,"type":20},"2024-10-01",{"date":118,"type":20},"2026-11-01",{"name":38,"class":39},""]